TwinBeech Capital’s Cytokinetics CYTK Stock Holding History

TwinBeech Capital’s Portfolio CYTK Stock Details CYTK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-32,714	Closed	-$964K	–	693
2023 Q3	$964K	Buy	+32,714	New	+$1.09M	0.02%	495
2022 Q4	–	Sell	-28,022	Closed	-$1.36M	–	741
2022 Q3	$1.36M	Buy	+28,022	New	+$1.35M	0.04%	400
2021 Q3	–	Sell	-19,207	Closed	-$380K	–	621
2021 Q2	$380K	Buy	+19,207	New	+$451K	0.05%	342

Other funds holding CYTK

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

TwinBeech Capital's CYTK Position: Q4 2023 in Review

TwinBeech Capital sold out of Cytokinetics (CYTK) in Q4 2023, closing a stake of 32,714 shares — an estimated $964K sold.

TwinBeech Capital first reported a position in CYTK in Q2 2021 and held it in 3 quarters. The position peaked at $1.36M in Q3 2022. 347 funds tracked by Wall St. Rank hold CYTK as of Q4 2023.

TwinBeech Capital reported no remaining Cytokinetics position as of Q4 2023 after selling out during the quarter.
TwinBeech Capital sold 32,714 Cytokinetics shares in Q4 2023, an estimated $964K.
TwinBeech Capital first reported a position in Cytokinetics in Q2 2021 and held it in 3 quarters.
TwinBeech Capital's Cytokinetics position peaked at $1.36M in Q3 2022.
347 funds tracked by Wall St. Rank held Cytokinetics as of Q4 2023.

Based on TwinBeech Capital's 13F filing for Q4 2023, filed 14 Feb 2024.